MARKET

HOOK

HOOK

Hookipa Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.01
-0.11
-0.99%
Closed 16:29 09/18 EDT
OPEN
11.32
PREV CLOSE
11.12
HIGH
11.43
LOW
10.86
VOLUME
350.64K
TURNOVER
--
52 WEEK HIGH
14.37
52 WEEK LOW
5.80
MARKET CAP
282.46M
P/E (TTM)
-7.0922
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article
Peer reviewed article in OncoImmunology demonstrates promising preclinical results for the novel cancer therapy targeting Human Papillomavirus 16 (HPV16) E6/E7 HPV is estimated to cause approximately 5% of the worldwide cancer burdenNEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA
GlobeNewswire · 4d ago
HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum
NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team
GlobeNewswire · 4d ago
HOOKIPA Pharma to Present at Upcoming Conferences in September
NEW YORK and VIENNA, Austria, Sept. 09, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team
GlobeNewswire · 09/09 11:30
HOOKIPA Pharma EPS beats by $0.19, beats on revenue
HOOKIPA Pharma (HOOK): Q2 GAAP EPS of -$0.28 beats by $0.19.Revenue of $6.69M (+65.2% Y/Y) beats by $3.2M.Press Release
Seekingalpha · 08/13 11:07
HOOKIPA Pharma Q2 EPS $(0.28) Beats $(0.47) Estimate, Sales $6.68M Beat $3.49M Estimate
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.47) by 40.43 percent. This is a 55.56 percent increase over losses of $(0.63) per share from
Benzinga · 08/13 11:06
HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/06 16:30
HOOKIPA Pharma To Report Second Quarter 2020 Financial Results on August 13, 2020
NEW YORK and VIENNA, Austria, Aug. 04, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today
GlobeNewswire · 08/04 11:00
HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/03 16:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HOOK stock price target is 19.00 with a high estimate of 24.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 8.16M
% Owned: 31.83%
Shares Outstanding: 25.65M
TypeInstitutionsShares
Increased
20
869.96K
New
16
137.64K
Decreased
9
362.52K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.38%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
Jan van de Winkel
Chief Executive Officer/Director
Joern Aldag
Chief Financial Officer/Director
Reinhard Kandera
Executive Vice President
Klaus Orlinger
Chief Technology Officer
Roman Necina
Other
Igor Matushansky
Independent Director
David Kaufman
Independent Director
Michael Kelly
Independent Director
Christoph Lengauer
Independent Director
Julie O Neill
Independent Director
Graziano Seghezzi
Independent Director
Sander van Deventer
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average HOOK stock price target is 19.00 with a high estimate of 24.00 and a low estimate of 15.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company offers VaxWave technology, which is designed to induce a robust CD8+ T cell and pathogen neutralizing response to fight disease. VaxWave technology supports the benefits of our arenavirus platform approach.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Hookipa Pharma Inc stock information, including NASDAQ:HOOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HOOK stock methods without spending real money on the virtual paper trading platform.